

Sudan, Republic of

**Support for Vaccine: Inactivated Polio Virus
This Decision Letter sets out the Programme Terms of a Programme.**

1.	Country:	Sudan, Republic of																					
2.	Vaccine grant number:	15-SDN-08h-Y, 1518-SDN-25c-X, 19-SDN-25c-X																					
3.	Date of Decision Letter:	11-Jul-19																					
4.	Date of the Partnership Framework Agreement:	December 10, 2013																					
5.	Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine																					
6.	Vaccine type:	Inactivated Polio Virus																					
7.	Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID																					
8.	Programme Duration: ¹	2015-2019																					
9.	Programme Budget (indicative): ²	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
		2015-2018	2019	2020	2021	2022	2023	Total ²															
	Programme Budget (US\$)	3,450,492	4,452,000	-	-	-	-	7,902,492															
10.	Vaccine introduction grant	<table border="1" style="width:100%; border-collapse: collapse; margin-bottom: 10px;"> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="width: 15%;">Year</th> <th style="width: 40%;">Grant Number</th> <th style="width: 45%;">Amount (US\$)</th> </tr> <tr> <td style="text-align: center;">2015</td> <td style="text-align: center;">15-SDN-08h-Y</td> <td style="text-align: right;">1,040,500</td> </tr> </table> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="width: 40%;">Disbursement date</th> <th style="width: 60%;">Amount (US\$)</th> </tr> <tr> <td style="text-align: center;">10 November, 2014</td> <td style="text-align: right;">1,040,500</td> </tr> </table>							Approval			Year	Grant Number	Amount (US\$)	2015	15-SDN-08h-Y	1,040,500	Disbursement		Disbursement date	Amount (US\$)	10 November, 2014	1,040,500
Approval																							
Year	Grant Number	Amount (US\$)																					
2015	15-SDN-08h-Y	1,040,500																					
Disbursement																							
Disbursement date	Amount (US\$)																						
10 November, 2014	1,040,500																						
11.	Product switch grant	Not applicable																					
12.	Indicative Annual Amounts: ³	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
	Type of supplies to be purchased with Gavi funds	2015-2018	2019					2020															
	Number of vaccine doses		1,942,000					-															
	Annual Amounts (US\$)	3,450,492	4,452,000					-															

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the total amount approved by Gavi.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
14. Self-procurement:	Not applicable	
15. Co-financing obligations:	Not applicable	
	Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.	
16. Operational support for catch-up campaigns:	Not applicable	
17. Additional Reporting Requirements:		
		Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		
<ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 		<p>March 31, 2020</p> <p>May 15, 2020</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		Intervals and dates of reporting to be agreed with Gavi Secretariat
18. Financial clarifications:	Country shall provide the following clarifications to Gavi*:	
	Not applicable.	
	* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
19. Other conditions:	Not applicable.	

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Sudan, Republic of envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Sudan, Republic of.

On behalf of Gavi



Pascal Bijleveld
Managing Director, Country Programmes a.i.